Pharming & Santarus submit Ruconest BLA as HAE treatment is launched in Europe
This article was originally published in Scrip
Executive Summary
Pharming and Santarus have submitted the BLA to the US FDA to obtain marketing approval for Rhucin (recombinant human C1 inhibitor) for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE).